Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Albendazole and Ivermectin for Lymphatic Filariasis
NCT00339417Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albendazole and ivermectin in lymphatic filariasis (LF) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Wuchereria bancrofti microfilarial levels at 12 months. Started Feb 2006; status: completed.
02
Drugs
albendazoleivermectin
03
Conditions
lymphatic filariasis (LF)
Beyond the preview
Go deeper on NCT00339417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00339417.